Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding


The objectives of this phase I study were to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and preliminary efficacy of intraperitoneally administered irinotecan (CPT-11) in gastric cancer patients with peritoneal seeding. Gastric adenocarcinoma patients with surgical biopsy proven peritoneal seeding were enrolled at the time… (More)
DOI: 10.1007/s00280-010-1272-6


6 Figures and Tables